At Rakovina Therapeutics, we believe in transparency and accountability, especially when it comes to matters related to our business, research, and communications. We are committed to providing accurate, timely, and responsible information about our operations and therapeutic advancements. To ensure clarity in our communications, we have developed a company-wide disclosure policy. We invite you to review this policy, which outlines how we handle disclosures, trading restrictions, and business relationships.

Commitment to Transparency

Rakovina Therapeutics is dedicated to advancing cancer therapies and sharing relevant updates with our stakeholders. Our communication principles are built on:

• Transparency: Openly sharing relevant company developments.

• Accountability: Ensuring that all disclosures meet legal and ethical standards.

• Responsibility: Delivering factual information that can guide informed decision-making.

Disclosure of Interests

• Employee Investments:

  • Rakovina Therapeutics allows employees and executives to hold positions in the company’s securities. However, these holdings must be disclosed when relevant.

  • Employees must disclose any beneficial interests in securities mentioned in public communications.

• Company Recommendations:

  • If Rakovina Therapeutics endorses or recommends any financial positions related to our business, this information will be disclosed at the time of communication.

Trading Restrictions

To maintain the highest standards of integrity, Rakovina Therapeutics enforces the following trading restrictions:

• Minimum Holding Period: Employees must hold any company stock for at least 10 days—no day trading is allowed.

• Trading Windows: Employees cannot trade company securities within two market days before or after public disclosures of material information.

• Compliance Approval: All trades must be cleared with our compliance department prior to execution.

• Mandatory Reporting: Employees must notify the compliance department upon buying or selling any company-related securities.

Business and Technology Partners

Rakovina Therapeutics collaborates with various business partners, including research institutions, data providers, technology vendors, and pharmaceutical companies. While some of these entities may be publicly traded, any mention or recommendation related to these companies in our communications is purely coincidental unless otherwise disclosed.

Communication with Investors

• Rakovina Therapeutics believes that informed investors are essential to our mission. We strive to:

  • Provide timely updates on research milestones, clinical trials, and corporate developments.

  • Disclose any potential conflicts of interest in our communications.

Service Providers and Major Partner: Our operations involve collaborations with

• Research and Development Partners: Leading universities, biotech firms, and research institutions.

• Financial and Legal Advisors: Reputable firms ensuring regulatory compliance and financial integrity.

• Technology Providers: Companies supporting our research infrastructure and operational efficiency.

Conclusion

Rakovina Therapeutics remains committed to upholding the highest standards of transparency, integrity, and responsibility. We encourage all stakeholders to consider our disclosures thoughtfully and conduct their own due diligence. Our disclosure policy is designed to foster trust, ensure ethical conduct, and support our mission of advancing cancer therapeutics.

For further inquiries about this disclosure policy, please contact our compliance department at info@rakovinatherapeutics.com